-
Featured
Low-risk Incidental Prostate Cancer in Men with Bladder Cancer May Be Associated with Longer Survival
Men with bladder cancer who have low-risk prostate cancer detected incidentally by radical cystoprostatectomy may actually have a more favorable prognosis than those who do not.
-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
New Target Discovered for Prostate Cancer Immunotherapy
Genitourinary pathologists at Massachusetts General Hospital are the first to demonstrate that PD-L1 expression is highly prevalent in prostate tumor-associated nerves. Such nerves may represent an important target for immunotherapy regimens.
-
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
Chin-Lee Wu, MD, PhD, Douglas M. Dahl, MD, and colleagues found that 15% of patients who had negative prostate multiparametric MRI (mpMRI) were diagnosed by 20-core standard template biopsy as having clinically significant prostate cancer. They recommend considering standard biopsy regardless of negative mpMRI.
-
Triple Therapy Prolongs Survival in High-Volume and Any-Risk Metastatic Hormone-sensitive Prostate Cancer
Matthew R. Smith, MD, PhD, and colleagues found that in patients with high-volume, high-risk, or low-risk metastatic hormone-sensitive prostate cancer, treatment with darolutamide, androgen-deprivation therapy, and docetaxel increased overall survival with a similar safety profile across subgroups.
-
Study Explores Value of Prostate Cancer Screening With MRI
The Prostate Cancer Genetics Program at Massachusetts General Hospital explores whether MRI prostate cancer screening detects disease earlier than standard tests in men with genetic mutations linked to prostate cancer.
Mass General Cancer Center Contributors
-
Adam S. Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Associate Chair for Research, Urologic Oncologist, Department of Urology, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School
Recent Article
Urine Test Validated for Diagnosis, Surveillance and Risk Prediction in Urothelial Carcinoma
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Douglas M. Dahl, MD
Chief, Division of Urologic Oncology, Vice-Chair, Department of Urology, Massachusetts General Hospital, Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Cancer Center, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
